Welcome to our dedicated page for Harmony Biosciences Holdings news (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings stock.
Harmony Biosciences Holdings, Inc. (HRMY) delivers innovative therapies for rare neurological and central nervous system disorders, with a focus on sleep/wake conditions. This page provides authorized updates on clinical developments, regulatory milestones, and corporate announcements directly impacting the company serves.
Investors and healthcare professionals will find timely updates on WAKIX commercialization, pipeline advancements in rare epilepsies, and strategic collaborations. Content includes earnings reports, FDA filings, research publications, and partnership announcements—all verified through primary sources.
Key coverage areas include pediatric narcolepsy treatment expansions, orexin receptor agonist trials, and neurobehavioral disorder research. Bookmark this page for consolidated access to Harmony Biosciences' progress in transforming care for underserved patient populations through novel therapeutic mechanisms.
On April 24, 2023, Harmony Biosciences (Nasdaq: HRMY) appointed Jeffrey M. Dayno, M.D., as President and Chief Executive Officer. Dr. Dayno, who has been with the company since its inception in 2017 and has served as Interim CEO since January 2023, aims to enhance the WAKIX franchise, targeting both narcolepsy and potential new indications. The Board supports his vision for growth, anticipating a $1 billion market opportunity for WAKIX. Harmony focuses on developing therapies for rare neurological diseases and has been successful in obtaining FDA approval for WAKIX, which has been available in the U.S. since Q4 2019. The company emphasizes its commitment to innovative treatments for patients, as highlighted by Dr. Dayno's extensive experience in the field.
Harmony Biosciences Holdings (NASDAQ: HRMY) announced that it will release its first quarter 2023 financial results on May 2, 2023, before the U.S. financial markets open. A conference call will be held on the same day at 8:30 a.m. ET to discuss the results. Investors can participate by dialing (800) 343-4136 for domestic calls or +1 (203) 518-9843 for international calls, referencing passcode HRMYQ123. The live and replayed webcast will be accessible on the company’s investor page.
Harmony Biosciences focuses on developing therapies for rare neurological diseases, emphasizing innovation and empathy. Established in 2017 and headquartered in Plymouth Meeting, PA, the company aims to improve the lives of patients suffering from these conditions.
FAQ
What is the current stock price of Harmony Biosciences Holdings (HRMY)?
What is the market cap of Harmony Biosciences Holdings (HRMY)?
